Baxter aims to divide and conquer


US drugmaker Baxter International is spinning off its biopharmaceuticals business to create two independent companies.

The biopharma unit will include Baxter’s existing plasma- and recombinant protein-based drugs for haemophilia, along with treatments for other blood-related conditions. The company stated that it will look to add to its pipeline of treatments and diagnostics for bleeding disorders through collaborations and acquisitions.

The remaining ‘medical products’ outfit includes Baxter’s dialysis equipment, as well as intravenous drug delivery systems, anaesthetics and surgical equipment. That business will aim to grow by increasing its geographical reach and streamlining costs.


Related Content

Baxter to pay $4bn for dialysis firm

6 December 2012 Business

news image

Gambro makes products for hemodialysis and continuous renal replacement therapy

10 years ago - Alain Baxter

1 May 2012 Flashback

news image

British Olympic skier Alain Baxter had his bronze medal taken away after a post-race drug test showed traces of methamphetami...

Most Read

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines

MDMA

9 October 2014 Podcast | Compounds

news image

The drug that fuelled rave culture may yet be a treatment for PTSD. Hayley Simon introduces MDMA

Most Commented

Helium happily shares electrons to create dianions

16 October 2014 Research

news image

Fullerene dianions created in nanodroplets of helium opening up new ways of creating exotic molecular species

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines